WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

• Published in: Turkish journal of haematology Vol. 37; no. 1; pp. 42 - 47
• Main Authors: Haznedaroğlu, İbrahim C., Kuzu, Işınsu, İlhan, Osman
• Format: Journal Article
• Language: English
• Published: Turkey Türk Hematoloji Derneği 20.02.2020; Galenos Publishing House; Galenos Publishing
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; chronic myeloid leukemia; cml; Combined Modality Therapy; Disease Management; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - etiology; Molecular Targeted Therapy - methods; Neoplasm Grading; Neoplasm Staging; Practice Guidelines as Topic; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; s in Hematology; Tıp; tki; Treatment Outcome; tyrosine kinase inhibitor; World Health Organization; İstanbul; Türkiye; CML; TKI; Chronic myeloid leukemia; Tyrosine kinase inhibitor; Tirozin kinaz inhibitör; Kronik myeloid lösemi; KML
• ISSN: 1300-7777; 1308-5263; 1308-5263
• DOI: 10.4274/tjh.galenos.2019.2019.0241

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be manageable with tyrosine kinase inhibitor (TKI) drugs. The aim of TKI drug treatment is to provide age- and sex-matched duration of life in a given patient with CML. Personalized CML treatment with TKI drugs is the key strategy. Individual treatment approach includes the harmonization of CML disease characteristics, clinical experience, and best available clinical evidence. Specific CML disease characteristics in a given patient include; CML disease risk, comorbidities, molecular profile, compliance, lifestyle, and drug off-target risk profile. CML research evidence includes; randomized clinical trials indicating the data on the efficacy, safety, tolerability, toxicity, possible long-term adverse events, and pharmacoeconomy of TKIs. Clinical and physician experience includes TKI availability, TKI reimbursability, drug experience, adherence, and BCR-ABL1 monitorization facilities. The key decision of choosing a TKI of choosing TKIs for CML should be made via the consideration of these variables. The aim of this paper is to outline the latest 2016 World Health Organization definition of CML and its proper management with TKI-class drugs.